SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFC14A - Definitive proxy statement, contested solicitations:
SEC Accession No. 0000921895-23-002070
Filing Date
2023-08-24
Accepted
2023-08-25 10:10:29
Documents
4

Document Format Files

Seq Description Document Type Size
1 defc14a13224004_08242023.htm DEFC14A 283705
2 GRAPHIC image_001.jpg GRAPHIC 23335
3 GRAPHIC image_002.jpg GRAPHIC 12789
4 GRAPHIC image_003.jpg GRAPHIC 12789
  Complete submission text file 0000921895-23-002070.txt   353117
Mailing Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247
Business Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247 (310) 618-6994
Forte Biosciences, Inc. (Subject) CIK: 0001419041 (see all company filings)

IRS No.: 261243872 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFC14A | Act: 34 | File No.: 001-38052 | Film No.: 231204189
SIC: 2834 Pharmaceutical Preparations

Mailing Address CAMAC CAPITAL, LLC 350 PARK AVENUE, 13TH FLOOR NEW YORK NY 10022
Business Address CAMAC CAPITAL, LLC 350 PARK AVENUE, 13TH FLOOR NEW YORK NY 10022 914-629-8496
Camac Fund, LP (Filed by) CIK: 0001516478 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFC14A